Upregulation of Bcl2 in NSCLC with acquired resistance to EGFR‑TKI-Reference-Cited by-同舟云学术

Upregulation of Bcl2 in NSCLC with acquired resistance to EGFR‑TKI

Published:2017-11-09 Issue: Volume: Page:
ISSN:1792-1074
Container-title:Oncology Letters
language:
Short-container-title:Oncol Lett

Author:

Cheong Hio Teng¹,Xu Fei²,Choy Chi Tung¹,Hui Connie Wun Chun¹,Mok Tony Shu Kam¹,Wong Chi Hang¹

Affiliation:

1. Department of Clinical Oncology, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, SAR, P.R. China

2. Sun Yat‑sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong 510000, P.R. China

Publisher

Spandidos Publications

Subject

Cancer Research,Oncology

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Vismodegib Potentiates Marine Antimicrobial Peptide Tilapia Piscidin 4-Induced Cytotoxicity in Human Non-Small Cell Lung Cancer Cells;Probiotics and Antimicrobial Proteins;2024-05-14

2. YES1 as a potential target to overcome drug resistance in EGFR-deregulated non-small cell lung cancer;Archives of Toxicology;2024-03-05

3. The cell line models to study tyrosine kinase inhibitors in non-small cell lung cancer with mutations in the epidermal growth factor receptor: A scoping review;Critical Reviews in Oncology/Hematology;2024-02

4. MGL S3 Chimeric Enzyme Drives Apoptotic Death of EGFR-Dependent Cancer Cells through ERK Downregulation;International Journal of Molecular Sciences;2022-10-24

5. Expression Level and Clinical Significance of AK021443 in Non-Small-Cell Lung Carcinoma;Journal of Healthcare Engineering;2022-03-14